Literature DB >> 28760238

Selected Controversies of Radioiodine Imaging and Therapy in Differentiated Thyroid Cancer.

Douglas Van Nostrand1.   

Abstract

This article discusses the more controversial areas of the management of differentiated thyroid cancer, namely, the utility of pretherapy staging radioiodine scans; the prescribed activity for iodine-131 remnant ablation, adjuvant treatment, and distant metastases; preparation with thyroid hormone withdrawal versus recombinant human thyroid-stimulating hormone; and the classification of radioiodine refractory differentiated thyroid cancer. The author reviews various aspects of the controversies, such as the recommendations of the 2015 guidelines of the American Thyroid Association, arguments for and against the various controversies, and selected references.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  I-131; I-131 adjuvant treatment; Radioiodine refractory disease; Radioiodine scanning; Remnant ablation; Thyroid cancer

Mesh：

Substances：

Year:  2017        PMID： 28760238     DOI： 10.1016/j.ecl.2017.04.007

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN： 0889-8529            Impact factor:   4.741


  6 in total

Review 1.  Controversial Issues in Thyroid Cancer Management.

Authors:  R Michael Tuttle
Journal:  J Nucl Med       Date:  2018-04-13       Impact factor: 10.057

2.  Novel recombinant human thyroid-stimulating hormone in aiding postoperative assessment of patients with differentiated thyroid cancer-phase I/II study.

Authors:  Yan-Song Lin; Hui Yang; Xiao-Yi Li; Li-Qing Wu; Jin-Guo Xu; Ai-Min Yang; Zai-Rong Gao; Yong Ding; Ying-Qiang Zhang; Kai Chen; Zhuan-Zhuan Mu; Jian-Min Jia; Na Niu; Di Sun; Xin Zhang; Shao-Qiang Zhang; Qian-Qian Geng; Ya-Jing Zhang; Fang-Ni Chen; Bao-Xia He
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-07-04       Impact factor: 10.057

3.  Less than 2% of the Low- and Intermediate-Risk Differentiated Thyroid Cancers Show Distant Metastases at Post-Ablation Whole-Body Scan.

Authors:  Laura Agate; Francesca Bianchi; Federica Brozzi; Pierina Santini; Eleonora Molinaro; Valeria Bottici; David Viola; Loredana Lorusso; Paolo Vitti; Rossella Elisei
Journal:  Eur Thyroid J       Date:  2018-12-13

Review 4.  Two decades of SPECT/CT - the coming of age of a technology: An updated review of literature evidence.

Authors:  Ora Israel; O Pellet; L Biassoni; D De Palma; E Estrada-Lobato; G Gnanasegaran; T Kuwert; C la Fougère; G Mariani; S Massalha; D Paez; F Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-04       Impact factor: 9.236

5.  Relationship of PPARG overexpression with prognostic parameters in papillary thyroid carcinoma.

Authors:  Orhan Asya; Ali Cemal Yumuşakhuylu; Pelin Bağcı; Handan Kaya; Ayşegül Gönen; Yavuz Gündoğdu; Tajaddın Muradov; Akın Şahin; Çağatay Oysu
Journal:  Acta Otorhinolaryngol Ital       Date:  2022-02       Impact factor: 2.618

6.  2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?

Authors:  Furio Pacini; Dagmar Fuhrer; Rossella Elisei; Daria Handkiewicz-Junak; Sophie Leboulleux; Markus Luster; Martin Schlumberger; Johannes W Smit
Journal:  Eur Thyroid J       Date:  2022-01-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.